Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

NCT04363827 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

155

Enrollment

OTHER

Sponsor class

Stopped Difficulties in recruiting subjects were observed soon after the study was initiated. This difficulty was attributed to the decreased incidence of infections which occurred in the period following the first lock down.

Conditions

COVID19
Hydroxychloroquine
Prophylaxis
Treatment
SARS-CoV-2

Interventions

DRUG: Hydroxychloroquine

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Collaborators

[object Object]